Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. 

Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. 

Its lead candidate, FLT201, is an AAV gene therapy for Gaucher disease that is poised to enter phase 3 development in 2025.

This week, we have a conversation with Michael Parini, CEO of Spur Therapeutics, about the future of gene therapy.

01:56-04:01: About Spur Therapeutics
04:01-06:49: Where is the gene therapy field at currently?
06:49-10:44: The biggest challenges for gene therapies, and potential solutions
10:44-13:21: What is the next generation of gene therapy?
13:21-18:08: How can gene therapy be used to take on more diseases? How can it be cheaper?
18:08-19:14: Are other companies working on next-generation gene therapies?
19:14-21:07: What is Gaucher disease?
21:07-22:32: How are you tackling Gaucher disease?
22:32-26:07: What is the measure of success?
26:07-28:18: About adrenomyeloneuropathy
28:18-29:32: Upcoming approvals in gene therapy
29:32-31:40: How quickly is gene therapy evolving?

This podcast is sponsored by Vetter, a globally leading CDMO, with over 70 years of experience as a responsible, independent family business. Driven by more than 6,600 employees worldwide, Vetter provides life-saving injectable drug products to the patients that rely on them most. Vetter partners with its customers throughout the entire product lifecycle, starting in the early phase of drug development with comprehensive expertise and support in clinical manufacturing for in-human trial material. For more information, visit vetter-pharma.com

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter